Raises Full Year 2013 Revenue Guidance Conference Call Scheduled for Today, July 1, at 9:00 a.m. ET IRVINE, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the second quarter ended June 30, 2013. Endologix (ELGX) anticipates second quarter 2013 global revenue of approximately $34.0 million, representing approximately 33% growth as compared to the second quarter of 2012 and 14% growth as compared to the first quarter of 2013. The Company anticipates U.S. revenue to be approximately $26.3 million in the second quarter 2013, representing approximately...
↧